HomeCompareLPCUF vs ORCC

LPCUF vs ORCC: Dividend Comparison 2026

LPCUF yields 3.16% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ORCC wins by $1.2K in total portfolio value
10 years
LPCUF
LPCUF
● Live price
3.16%
Share price
$0.19
Annual div
$0.01
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.2K
Annual income
$0.32
Full LPCUF calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — LPCUF vs ORCC

📍 ORCC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLPCUFORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LPCUF + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LPCUF pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LPCUF
Annual income on $10K today (after 15% tax)
$268.66/yr
After 10yr DRIP, annual income (after tax)
$0.27/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, ORCC beats the other by $0.61/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LPCUF + ORCC for your $10,000?

LPCUF: 50%ORCC: 50%
100% ORCC50/50100% LPCUF
Portfolio after 10yr
$20.8K
Annual income
$0.68/yr
Blended yield
0.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

LPCUF
No analyst data
Altman Z
2.8
Piotroski
8/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LPCUF buys
0
ORCC buys
0
No recent congressional trades found for LPCUF or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLPCUFORCC
Forward yield3.16%9.79%
Annual dividend / share$0.01$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%-50%
Portfolio after 10y$20.2K$21.4K
Annual income after 10y$0.32$1.04
Total dividends collected$319.00$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: LPCUF vs ORCC ($10,000, DRIP)

YearLPCUF PortfolioLPCUF Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$10,858$158.04$11,190$489.61$332.00ORCC
2$11,698$80.19$12,229$256.01$531.00ORCC
3$12,558$40.37$13,216$130.74$658.00ORCC
4$13,457$20.25$14,207$66.02$750.00ORCC
5$14,409$10.14$15,234$33.17$825.00ORCC
6$15,423$5.07$16,317$16.62$894.00ORCC
7$16,505$2.54$17,468$8.32$963.00ORCC
8$17,661$1.27$18,695$4.16$1.0KORCC
9$18,898$0.63$20,006$2.08$1.1KORCC
10$20,221$0.32$21,407$1.04$1.2KORCC

LPCUF vs ORCC: Complete Analysis 2026

LPCUFStock

Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. The company focuses on various disease areas, including cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, obstetrics, and urology. It operates through Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells self-developed and generic pharmaceutical products, such as Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Eyprotor for corneal ulcers; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat Urea cycle disorders. The Licensed-In Products segment trades in licensed-in pharmaceutical products, including Carnitene for the treatment of carnitine deficiency; Aloxi and Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renaltransplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; Episil to treat oral mucositis pain; Ferplex to treat iron deficiency anemia; and Gaslon N for gastric ulcer and gastritis. This segment also offers Intrarosa for vulvovaginal atrophy; Levocarnitine oral solution to treat primary and secondary carnitine deficiency; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Omacor to treat Omega-3-acid ethyl esters; Zanidip and Rasilez for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Unidrox for urinary and respiratory tract infections; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.

Full LPCUF Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this LPCUF vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LPCUF vs SCHDLPCUF vs JEPILPCUF vs OLPCUF vs KOLPCUF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.